In this study, we investigate the role of signal transducer and activator of transcription 3 (STAT3) in treatment-induced adaptive survival of ALK-rearranged lung cancer cells and evaluate the preclinical antitumor activities of STAT3-targeting combination therapy using ALK-rearranged lung cancer cell lines and a xenograft model. This evidence concerns the gene STAT3 and lung carcinoma.